GlassScriptPhysician profile
William L Musgrave
NPI 1770898306
$20,647.72
in general payments reported to CMS, 2019-2025
85 companies · $3,269 in 2025
The $3,269 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,611 · 2020: $2,289 · 2021: $4,594 · 2022: $2,955 · 2023: $2,835 · 2024: $3,096 · 2025: $3,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,167 · Education: $32.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,167.44 |
| Education | $32.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,826.15 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,575.50 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Biohaven Pharmaceuticals, INC. | $1,384.34 | 2021 | |
| Novo Nordisk INC | $1,334.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,170.19 | 2019-2025 | |
| Axsome Therapeutics, INC. | $832.08 | 2023-2025 | Sunosi, Auvelity |
| Glaxosmithkline, LLC. | $815.01 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Scilex Pharmaceuticals INC. | $770.33 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $737.33 | 2019-2025 | Jardiance |
| Amgen INC. | $697.22 | 2019-2025 | Repatha, Evenity, Otezla |
| Antares Pharma, INC. | $680.77 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Bayer Healthcare Pharmaceuticals INC. | $568.77 | 2021-2025 | |
| Corium, LLC | $547.38 | 2022-2025 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $477.70 | 2020-2025 | Qelbree, Xyosted, Qelbree |
| Lilly USA, LLC | $463.63 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
Show all 85 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Musgrave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.